Renexxion
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Latest Regulatory Developments
  • Knowledge Center
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • ​GERD
    • Functional Dyspepsia
    • Gastroparesis
    • Other Therapeutic Indications
  • News
    • Press >
      • Sinovant Sciences and Renexxion Form Partnership to Develop Naronapride in China BEIJING, SHANGHAI, and Menlo Park
      • Renexxion Achieves Positive FDA Guidance for Phase 3 ready GI Drug Naronapride
  • Contact

    Contact

    Renexxion
    325 Sharon Park Drive, #303
    Menlo Park, CA 94025

    Tel. No. +1 650 924 9895 / +1 650 376 0598
    Fax.       +1 415 449 3581
     

    Business Development enquiries:  bd(at)renexxion(dot)com
    Press and media enquiries:  press(at)renexxion(dot)com
    Please replace (at) and (dot) with their respective symbols as in  example@renexxion.com 


Submit
Privacy Policy & Terms of Use 
​Copyright Renexxion 2016. All rights reserved.
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Latest Regulatory Developments
  • Knowledge Center
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • ​GERD
    • Functional Dyspepsia
    • Gastroparesis
    • Other Therapeutic Indications
  • News
    • Press >
      • Sinovant Sciences and Renexxion Form Partnership to Develop Naronapride in China BEIJING, SHANGHAI, and Menlo Park
      • Renexxion Achieves Positive FDA Guidance for Phase 3 ready GI Drug Naronapride
  • Contact